1. Signaling Pathways
  2. Epigenetics
  3. Epigenetic Reader Domain
  4. Epigenetic Reader Domain Degrader

Epigenetic Reader Domain Degrader

Epigenetic Reader Domain Degraders (68):

Cat. No. Product Name Effect Purity
  • HY-163410
    AU-24118
    Degrader 99.10%
    AU-24118 is orally bioavailable proteolysis targeting chimera (PROTAC) degrader of mSWI/SNF ATPases (SMARCA2 and SMARCA4) and PBRM1.
  • HY-117690
    dBRD9
    Degrader 99.89%
    dBRD9,a PROTAC, can selective degrades BRD9. dBRD9 improves the bromine domain binding profile and reduces the binding activity of the whole BET family.
  • HY-153385
    TMX1
    Degrader 99.09%
    TMX1 is a BRD4 covalent molecular glue degrader. TMX1 selectively recruits DCAF16 to BRD4BD2, resulting in the degradation of BRD4.
  • HY-156568B
    SMD-3040 formate
    Degrader 99.90%
    SMD-3040 formate is a potent and selective smarca2 protac degrader with strong in vivo antitumor activity.
  • HY-101460
    Tz-Thalidomide
    Degrader 98.01%
    Tz-Thalidomide is a tetrazine tagged Thalidomide (HY-14658) (Ligands for E3 Ligase). Tz-Thalidomide has binding affinity for BRD4, with IC50s of 46.25 μM (BRD4-1) and 62.55 μM (BRD4-2). Tz-Thalidomide is a click chemistry reagent, it contains a Tetrazine group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing TCO groups.
  • HY-153459
    PROTAC BRD4 Degrader-19
    Degrader 98.83%
    PROTAC BRD4 Degrader-19 (compound 176) is a PROTAC that targets BRD4 protein for degradation. PROTAC BRD4 Degrader-19 can be used in cancer research.
  • HY-157592
    MMH2-NR
    Degrader 98.72%
    MMH2-NR a negtive control of MMH2. MMH2 is a CUL4-associated factor (DCAF16)-based bromodomain protein 4 (BRD4) degrader.
  • HY-139707
    Thalidomide-NH-CBP/p300 ligand 2
    Degrader 98.55%
    Thalidomide-NH-CBP/p300 ligand 2 (P-007) is a PROTAC-based CBP and p300 degrader (extracted from patent WO2020173440).
  • HY-156568A
    SMD-3040 TFA
    Degrader 99.90%
    SMD-3040 TFA is a selective degrader of SMARCA2. SMD-3040 TFA contains SMARCA2/4 ligands, linker and VHL ligands and can be used for PROTAC drug synthesis. SMD-3040 TFA exhibits strong tumor growth inhibition in tumor xenograft models.
  • HY-158764
    PROTAC BET Degrader-12
    Degrader 98.10%
    PROTAC BET Degrader-12 (Compound 8b) is a PROTAC degrader for bromodomain and extra-terminal domain (BET)-containing proteins, which degrades the BRD3 and BRD4 in a DCAF11-dependent manner. PROTAC BET Degrader-12 inhibits cell viability of KBM7 with a DC50 of 305.2 nM. (Pink: ligand for target protein (+)-JQ-1 (HY-13030); Black: linker (HY-159077); Blue: ligand for E3 ligase (HY-159076))
  • HY-149878
    BD-9136
    Degrader 98.81%
    BD-9136 is a highly selective BRD4 degrader. BD-9136 can inhibit tumor growth without adverse effects on mice. BD-9136 can be used for the research of cancer. BD-9136 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-136857
    BRD4 degrader-3
    Degrader
    BRD4 degrader-3 is a potent bromodomain BRD4 degrader extracted from patent WO2020055976A1, example 1a, has IC50s of 15.5 and 12.3 nM for BRD4-BD1 and BRD4-BD2, respectively. PROTAC BRD4 Degrader-7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-156568
    SMD-3040
    Degrader 99.91%
    SMD-3040 is a potent and selective of SMARCA2 PROTAC degrader (DC50: 12 nM). SMD-3040 contains SMARCA2/4 ligand, linker and VHL ligand. SMD-3040 demonstrates excellent degradation selectivity for SMARCA2 protein over SMARCA4 protein.SMD-3040 achieves strong tumor growth inhibition in xenograft models.
  • HY-107425A
    cis-MZ 1
    Degrader
    cis-MZ 1 is a negative control of MZ 1 (HY-107425). cis-MZ 1 is a PROTAC.html" class="link-product" target="_blank">PROTAC targeting to BRD4.
  • HY-138636
    PROTAC BRD4 Degrader-13
    Degrader
    PROTAC BRD4 Degrader-13 (compound 9d) is a von Hippel-Lindau system-based PROTAC BRD4 degrader with a linker that can be coupled to ADC antibodies to form PACs (PROTAC-antibody Conjugates). PROTAC BRD4 Degrader-13 can be coupled to STEAP1 and CLL1 antibodies to degrade BRD4 protein in PC3 prostate cancer cells with DC50 values ​​of 0.025 nM and 6.0 nM, respectively.
  • HY-161346
    EBET-1055
    Degrader
    EBET-1055 is a bromodomain and extra-terminal (BET) protein degrader (EBET) composed of a BET inhibitor (EBET-590, HY-161387), an E3 ubiquitin ligase ligand and connectors. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures.
  • HY-153632
    PROTAC BRD9 Degrader-6
    Degrader 98.19%
    PROTAC BRD9 Degrader-6 is a potent degrader of BRD9 (IC50=0.13 nM), can be used for research of BAF complex-related disorders.
  • HY-156744
    DBr-1
    Degrader
    DBr-1 is a potent BRD9 degrader.
  • HY-163638
    BRD4 degrader-1
    Degrader
    BRD4 degrader-1 (Compound ML 1-50) is a monovalent and covalent molecular glue BRD4 degrader. BRD4 degrader-1 targets DCAF16 (E3 ligase) and degrades both the long and short isoforms of BRD4 in cells.
  • HY-163871
    PROTAC SMARCA2/4-degrader-18
    Degrader
    PROTAC SMARCA2/4-degrader-18 (Compound I-348) is a PROTAC degrader for catalytic subunit of the SWI/SNF complex SMARCA2 and SMARCA4. PROTAC SMARCA2/4-degrader-18 degrades SMARCA2 in A549 with DC50 <100 nM, degrades SMARCA4 in MV411 with DC50 <100 nM. (Pink: Ligand for Target Protein (HY-159531); Black: Linker (HY-76547); Blue: Ligand for E3 Ligase (HY-125845))